First Time Loading...

Thalys Medical Technology Group Inc
SSE:603716

Watchlist Manager
Thalys Medical Technology Group Inc Logo
Thalys Medical Technology Group Inc
SSE:603716
Watchlist
Price: 6.79 CNY -2.58%
Updated: May 29, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

3.3B
-11%
Assets
Growth Rates:
1 Year
-15%
3 Years
-14%
5 Years
+29%
7 Years
+206%
10 Years
-
2.1B
-10%
Liabilities
Growth Rates:
1 Year
-16%
3 Years
-6%
5 Years
+101%
7 Years
+756%
10 Years
-
1.2B
-13%
Equity
Growth Rates:
1 Year
-14%
3 Years
-27%
5 Years
-20%
7 Years
+44%
10 Years
-

Balance Sheet Decomposition
Thalys Medical Technology Group Inc

3.3B
Assets
2.1B
Liabilities
3.3B
Assets
2.1B
Liabilities
Current Assets 2.4B
Cash & Short-Term Investments 263.8m
Receivables 1.7B
Other Current Assets 430.7m
Non-Current Assets 947.1m
Long-Term Investments 324.1m
PP&E 204.2m
Intangibles 150.1m
Other Non-Current Assets 268.7m
Current Liabilities 1.4B
Accounts Payable 746.2m
Accrued Liabilities 45.6m
Short-Term Debt 451.8m
Other Current Liabilities 151.9m
Non-Current Liabilities 735.4m
Long-Term Debt 596.8m
Other Non-Current Liabilities 138.7m

Balance Sheet
Thalys Medical Technology Group Inc

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
67
97
354
197
703
508
653
466
337
264
Cash
0
0
0
0
1
0
0
466
337
260
Cash Equivalents
67
97
354
196
702
508
652
0
0
4
Short-Term Investments
0
0
0
0
0
2
0
12
0
0
Total Receivables
260
310
404
617
905
1 286
1 767
2 182
2 032
1 700
Accounts Receivables
241
273
360
577
852
1 143
1 515
1 752
1 794
1 552
Other Receivables
19
38
44
41
54
144
252
430
239
148
Inventory
56
66
76
202
274
349
402
464
421
342
Other Current Assets
24
33
56
94
68
84
107
119
160
89
Total Current Assets
406
506
890
1 109
1 951
2 229
2 928
3 242
2 951
2 395
PP&E Net
100
123
161
211
239
247
271
277
234
204
PP&E Gross
100
123
161
211
239
247
271
277
234
204
Accumulated Depreciation
67
94
129
178
227
286
354
425
430
406
Intangible Assets
8
8
8
7
9
11
32
31
30
34
Goodwill
0
0
0
113
121
154
155
155
142
116
Note Receivable
0
0
0
0
75
75
69
62
50
43
Long-Term Investments
18
18
18
75
102
131
325
385
383
324
Other Long-Term Assets
5
9
16
54
86
160
127
141
169
226
Other Assets
0
0
0
113
121
154
155
155
142
116
Total Assets
538
N/A
663
+23%
1 093
+65%
1 569
+44%
2 583
+65%
3 007
+16%
3 906
+30%
4 294
+10%
3 959
-8%
3 342
-16%
Liabilities
Accounts Payable
19
26
9
56
99
236
400
565
720
746
Accrued Liabilities
10
14
21
30
36
43
49
55
61
46
Short-Term Debt
61
98
141
287
671
809
709
691
796
452
Current Portion of Long-Term Debt
0
17
0
20
9
0
0
110
67
9
Other Current Liabilities
18
27
36
140
119
232
230
316
192
142
Total Current Liabilities
108
182
207
532
934
1 320
1 388
1 737
1 836
1 395
Long-Term Debt
23
4
25
30
10
50
704
799
559
597
Deferred Income Tax
0
0
0
0
4
5
5
6
17
13
Minority Interest
7
10
16
70
105
132
155
181
94
104
Other Liabilities
1
7
1
4
9
11
7
9
49
22
Total Liabilities
138
N/A
203
+46%
249
+23%
636
+156%
1 062
+67%
1 518
+43%
2 259
+49%
2 731
+21%
2 556
-6%
2 131
-17%
Equity
Common Stock
38
38
51
71
205
205
205
205
204
202
Retained Earnings
171
233
302
392
479
595
637
611
457
300
Additional Paid In Capital
190
190
491
471
925
849
857
854
834
820
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
2
2
30
Treasury Stock
0
0
0
0
88
162
151
201
188
176
Other Equity
0
0
0
0
0
3
99
94
94
95
Total Equity
399
N/A
461
+15%
844
+83%
933
+11%
1 521
+63%
1 489
-2%
1 648
+11%
1 562
-5%
1 403
-10%
1 211
-14%
Total Liabilities & Equity
538
N/A
663
+23%
1 093
+65%
1 569
+44%
2 583
+65%
3 007
+16%
3 906
+30%
4 294
+10%
3 959
-8%
3 342
-16%
Shares Outstanding
Common Shares Outstanding
134
134
178
178
200
205
205
205
204
202

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.